5-Amino-1MQ: The Powerful NNMT Inhibitor Redefining Metabolic & Longevity Research in 2025

In the fast-moving world of metabolic and anti-aging science, 5-Amino-1MQ has quickly become one of the most talked-about research compounds. This selective nicotinamide N-methyltransferase (NNMT) inhibitor works by preserving cellular NAD⁺ levels, shifting energy balance toward fat burning, and supporting mitochondrial health — all without changing food intake or requiring exercise. If you’re searching for “5-Amino-1MQ benefits,5-Amino-1MQ weight loss research, or 5-Amino-1MQ 2025 studies, this is the complete, designer-ready guide you need.

Important: 5-Amino-1MQ is strictly a research chemical. It is not approved by the FDA for human use, diagnosis, or treatment. All information below is for laboratory and educational purposes only.

What Exactly Is 5-Amino-1MQ?

5-Amino-1MQ (full name: 5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor with the chemical formula C₉H₁₁N₃ and a molecular weight of ~161.2 Da. Its structure — a quinolinium ring with an amino group at position 5 and a methyl group on the nitrogen — gives it excellent cell permeability and high selectivity for NNMT (IC₅₀ ≈ 100 nM).

In research settings it appears as a white to off-white lyophilized powder, typically supplied in 10–100 mg vials with ≥99% purity (HPLC-verified). From our lab experience at Synthesis Peptides, it reconstitutes cleanly in bacteriostatic water and remains stable when stored at −20 °C.

How 5-Amino-1MQ Works: The Core Mechanism

NNMT is highly expressed in adipose tissue and many cancers. It converts nicotinamide into 1-methylnicotinamide (MNA), which depletes cellular NAD⁺ and promotes fat storage. By potently blocking NNMT, 5-Amino-1MQ:

• Preserves and elevates NAD⁺ levels
• Activates SIRT1 (the “longevity sirtuin”)
• Upregulates AMPK and GLUT4 expression
• Shifts adipocytes from lipid storage to oxidation
• Enhances mitochondrial biogenesis and function

The net result in preclinical models: significant fat mass reduction, improved insulin sensitivity, preserved lean muscle, and better lipid profiles — all without appetite suppression.

Key Research Benefits Observed (2024–2025 Data)

Latest 2025 Research Highlights

• 2025 studies continue to show strong anti-obesity effects via NNMT knockdown and microbiome modulation
• Emerging data on selective cytotoxicity in drug-resistant cancer lines (NAD⁺ depletion in tumor cells)
• Increased interest in combining 5-Amino-1MQ with NAD⁺ precursors or mitochondrial peptides for synergistic protocols

Practical Lab & Research Guidelines

Typical research protocols:

• In vitro: 1–50 µM in culture media
• In vivo (mice): 20–100 mg/kg daily (oral or subcutaneous)
• Anecdotal human-equivalent range (research discussion only): 50–150 mg/day, cycled 6–12 weeks

Reconstitution: 1–2 mL bacteriostatic water per 50 mg vial → clear solution

Storage: Lyophilized at −20 °C; reconstituted 2–8 °C up to 4 weeks

Observed side-effect profile in models: minimal (occasional mild GI discomfort at very high doses).

How 5-Amino-1MQ Compares to Other Popular Research Compounds

Frequently Asked Questions

Q: Does 5-Amino-1MQ suppress appetite?

A: No — weight loss occurs through metabolic reprogramming, not reduced food intake.

Q: Is it orally bioavailable?

A: Yes, excellent oral and subcutaneous absorption in preclinical models.

Q: Any new applications in 2025?

A: Growing interest in oncology and sarcopenia prevention.

Final Thoughts

With clean, reproducible effects on fat mass, NAD⁺ levels, and insulin sensitivity, 5-Amino-1MQ has cemented itself as a cornerstone compound for metabolic, longevity, and even oncology research in 2025 and beyond. At Synthesis Peptides, we’ve seen labs repeatedly return to it for its reliability and dramatic visual results in adipose tissue assays.

Disclaimer: This article is for informational and research purposes only. 5-Amino-1MQ is sold strictly for laboratory use and is not for human consumption. No statements have been evaluated by the FDA.